Century Therapeutics (IPSC) FCF Margin (2022 - 2025)

Century Therapeutics (IPSC) has 4 years of FCF Margin data on file, last reported at 32.15% in Q1 2025.

• FCF Margin for Q1 2025 came in at 32.15%, up 356867.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 95.93% (up 158751.0% YoY), and the FY2025 annual result was 95.93%, up 157790.0% from the prior year.
• FCF Margin advanced to 32.15% in Q1 2025 per IPSC's latest filing, from 580.47% in the prior quarter.
• Over five years, FCF Margin peaked at 7840.93% in Q1 2022 and troughed at 23989.9% in Q2 2023.
• A 4-year average of 4236.94% and a median of 2170.01% in 2022 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2023 and 2024: FCF Margin slumped 2240874 bps in 2023, then surged 2041052 bps in 2024.
• A 4-year view of FCF Margin shows it stood at 235.12% in 2022, then slumped by 4218 bps to 10152.99% in 2023, then surged by 94 bps to 580.47% in 2024, then jumped by 94 bps to 32.15% in 2025.
• Business Quant data shows IPSC's FCF Margin at 32.15% in Q1 2025, 580.47% in Q4 2024, and 3581.8% in Q3 2024.